SynthesisThe FEBS journal2026
Effects of GLP-1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review.
Synthesis in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a metabolic disease characterised by chronic hyperglycemia. The Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) used in type 2 diabetes mellitus (T2DM) have been highlighted for their potential benefits to the gut microbiota in the context of this pathology. Therefore, it is important to investigate the relationship between microbiota and GLP-1 RAs used in T2DM. This review aimed at evaluating the effects of GLP-1 agonists on gut microbiota in T2DM individuals. The protocol was previously registered in PROSPERO, and the search was conducted in PubMed, Scopus, Web of Science, and Embase databases in March 2025. Two reviewers have read the titles and abstracts and selected the included articles based on established criteria. The initial search identified 5532 publications, of which 17 studies were included: 12 preclinical and 5 clinical. Most were conducted in China between 2016 and 2025. GLP-1 agonists have been shown to modulate the gut microbiota, characterised by an increase in Bacteroidetes, Akkermansia muciniphila, and Lactobacillus. These changes are accompanied by an improvement of intestinal villi, increase in occludin expression, as well as an improvement in colonic inflammation. We identified a higher abundance of bacterial species associated with intestinal balance (eubiosis), accompanied by reduced inflammation and insulin resistance. Conversely, there was a lower abundance of bacteria related to dysbiosis, such as Firmicutes and Proteobacteria, which can be unfavourable when in excess. GLP-1 agonists influence the intestinal microbiota, improving metabolic parameters and anti-inflammatory effects. However, further clinical studies are needed to corroborate the findings of this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.